REFERENCES
1. Franco MS, Oliveira MC. Liposomes co- encapsulating anticancer drugs in synergistic ratios as an approach to promote increased efficacy and greater safety. Anticancer Agents Med Chem 2019;19:17-28.
2. Tolcher AW, Mayer LD. Improving combination cancer therapy: the CombiPlex(®) development platform. Future Oncol (London, England) 2018;14:1317-32.
3. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin oncol 2018;36:2684-92.
4. Shmeeda H, Amitay Y, Gorin J, et al. Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer. J Drug Target 2016;24:878-89.
5. Hodgins NO, Wang JT, Al-Jamal KT. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy. Adv Drug Deliv Rev 2017;114:143-60.
6. La-Beck NM, Liu X, Shmeeda H, Shudde C, Gabizon AA. Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment. Semin Cancer Biol 2019; doi: 10.1016/j.semcancer.2019.12.001.
7. Luo S, Gu Y, Zhang Y, et al. Precise ratiometric control of dual drugs through a single macromolecule for combination therapy. Mol Pharm 2015;12:2318-27.
8. Cheung RY, Rauth AM, Ronaldson PT, Bendayan R, Wu XY. In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin. Eur J Pharm Biopharm 2006;62:321-31.
9. Cheung RY, Rauth AM, Yu Wu X. In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations. Anticancer Drugs 2005;16:423-33.
10. Maitra R, Halpin PA, Karlson KH, et al. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression. Biochem J 2001;355:617-24.
11. Ihnat MA, Lariviere JP, Warren AJ, et al. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clin Cancer Res 1997;3:1339-46.
12. Ihnat MA, Nervi AM, Anthony SP, et al. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice. Oncol Res 1999;11:303-10.
13. Shuhendler AJ, O’Brien PJ, Rauth AM, Wu XY. On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells. Drug Metabol Drug Interact 2007;22:201-33.
14. Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat 2010;119:255-69.
15. Prasad P, Cheng J, Shuhendler A, Rauth AM, Wu XY. A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells. Drug Deliv Transl Res 2012;2:95-105.
16. Shuhendler AJ, Prasad P, Zhang RX, et al. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Mol Pharm 2014;11:2659-74.
17. Prasad P, Shuhendler A, Cai P, Rauth AM, Wu XY. Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts. Cancer Lett 2013;334:263-73.
18. Gabizon A, Shmeeda H, Tahover E, et al. Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: from bench to bedside. Adv Drug Deliv Rev 2020;154-155:13-26.
19. Amitay Y, Shmeeda H, Patil Y, et al. Pharmacologic studies of a prodrug of mitomycin C in pegylated liposomes (Promitil®): high stability in plasma and rapid thiolytic prodrug activation in tissues. Pharm Res 2016;33:686-700.
20. Golan T, Grenader T, Ohana P, et al. Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. Cancer Med 2015;4:1472-83.
21. Patil Y, Shmeeda H, Amitay Y, Ohana P, Kumar S, Gabizon A. Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA). Nanomedicine 2018;14:1407-16.
22. Gabizon A, Goren D, Cohen R, Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J Control Release 1998;53:275-9.
23. Wei X, Patil Y, Ohana P, et al. Characterization of pegylated liposomal mitomycin c lipid-based prodrug (Promitil) by high sensitivity differential scanning calorimetry and cryogenic transmission electron microscopy. Mol Pharm 2017;14:4339-45.
24. Beheshti A, Ghaffari S, Farahani H. Determination of cholesterol and its derivatives in nanoliposomes as drug delivery conveyances by HPLC-UV: a simple, accurate and cost-effective method development and validation approach. J Chromatogr Sci 2019;57:469-75.
25. Patil Y, Amitay Y, Ohana P, Shmeeda H, Gabizon A. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity. J Control Release 2016;225:87-95.
26. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002;10:539-48.
27. Wei X, Cohen R, Barenholz Y. Insights into composition/structure/function relationships of Doxil® gained from “high-sensitivity” differential scanning calorimetry. Eur J Pharm Biopharm 2016;104:260-70.
28. Gabizon AA, Patil Y, La-Beck NM. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Updat 2016;29:90-106.
29. Peretz Damari S, Shamrakov D, Varenik M, et al. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes. Int J Pharm 2018;547:648-55.
30. Schilt Y, Berman T, Wei X, Barenholz Y, Raviv U. Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs. Biochim Biophys Acta 2016;1860:108-19.
31. Horowitz AT, Barenholz Y, Gabizon AA. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta 1992;1109:203-9.
32. Gabizon AA, de Rosales RTM, La-Beck NM. Translational considerations in nanomedicine: the oncology perspective. Adv Drug Deliv Rev 2020;158:140-57.
33. Gabizon AA, Tzemach D, Horowitz AT, Shmeeda H, Yeh J, Zalipsky S. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin Cancer Res 2006;12:1913-20.
34. Gabizon A, Chemla M, Tzemach D, Horowitz AT, Goren D. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target 1996;3:391-8.
35. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000;6:1949-57.
36. Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. CPX-351 (vyxeos) in AML. Leuk Lymphoma 2020;61:288-97.
37. Feldman EJ, Lancet JE, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 2011;29:979-85.
38. Zhang RX, Cai P, Zhang T, et al. Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. Nanomedicine 2016;12:1279-90.
39. Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev 2018;130:17-38.
40. Doyle LA, Ihde DC, Carney DN, et al. Combination chemotherapy with doxorubicin and mitomycin C in non small cell bronchogenic carcinoma: Severe pulmonary toxicity from q 3 weekly mitomycin C. Am J Clin Oncol 1984;7:719-24.
42. Toy R, Hayden E, Shoup C, Baskaran H, Karathanasis E. The effects of particle size, density and shape on margination of nanoparticles in microcirculation. Nanotechnology 2011;22:115101.
43. Zocchi MR, Tosetti F, Benelli R, Poggi A. Cancer nanomedicine special issue review anticancer drug delivery with nanoparticles: extracellular vesicles or synthetic nanobeads as therapeutic tools for conventional treatment or immunotherapy. Cancers (Basel) 2020;12:1886.
44. Gabizon A, Amitay Y, Tzemach D, Gorin J, Shmeeda H, Zalipsky S. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. J Control Release 2012;160:245-53.
45. Rios-Doria J, Durham N, Wetzel L, et al. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models. Neoplasia (New York, NY) 2015;17:661-70.
46. Edmonds S, Volpe A, Shmeeda H, et al. Exploiting the metal-chelating properties of the drug cargo for in vivo positron emission tomography imaging of liposomal nanomedicines. ACS Nano 2016;10:10294-307.
47. Gawne P, Man F, Fonslet J, et al. Manganese-52: applications in cell radiolabelling and liposomal nanomedicine PET imaging using oxine (8-hydroxyquinoline) as an ionophore. Dalton Trans 2018;47:9283-93.
48. Man F, Lim L, Volpe A, et al. In Vivo PET tracking of (89)Zr-Labeled Vgamma9Vdelta2 T cells to mouse xenograft breast tumors activated with liposomal alendronate. Mol Ther 2019;27:219-29.
